Urologics
At Allergan, we recognize the serious implications of urologic disorders including overactive bladder (OAB), a medical condition that affects 33 million Americans and is only expected to grow in prevalence as the population ages.1 In 2007, Allergan created a dedicated Urologics division within the organization to focus on meeting the needs of urologists and their patients.
Allergan is investing significant resources to develop a product portfolio that addresses the full continuum of care for patients with OAB and other urological and genitourinary disorders. Allergan’s current product in this portfolio is SANCTURA XR™, a once-daily medication for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency approved in 2007 by the U.S. Food and Drug Administration.
In addition to our current products for OAB, we are continuing to research and develop new treatments for urologic disorders. Globally, we are currently in Phase III clinical trials investigating the use of BOTOX® (Botulinum Toxin Type A) for the treatment of neurogenic OAB - that is, OAB secondary to multiple sclerosis or spinal cord injury, or other neurologic dysfunction. And we are in the midst of Phase II clinical trials of BOTOX® for idiopathic OAB (in which the cause is unknown) – by far the most common form of the disorder. In addition, Allergan is studying the use of BOTOX® neurotoxin in a Phase II clinical trial for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia, a non-cancerous disease of the prostate that can interfere with urination and is one of the most common diseases among men.